Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Nerdwallet Inc (NRDS) Price & Performance

ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.

Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.

NRDS trades at $9.47, down 1.56% today, with a bullish technical signal from moving averages and strong fundamentals including a 93% gross margin and three consecutive earnings beats. Revenue grew to $837M in 2025, with net income reaching $49M. Analyst consensus is Buy with a $12.75 target, implying 35% upside. Positive news highlights the company's pivot to higher-margin transactions and launch of a Financial Resilience Index.

The outlook is positive given undervaluation (P/E 10.18, P/S 0.83) and earnings momentum, but risks include search traffic dependence and projected negative cash flow in 2026. Institutional sentiment is bullish with 66% Buy ratings, supporting a constructive view for long-term investors seeking growth at a reasonable price.